A Resource Guide to Investing in Biotechnology
Directory - Encyclopedia - Stock Index - Drugs  

Biotech100 Stock Index

Introgen Therapeutics

About Introgen

Introgen Therapeutics (NASDAQ®: INGN) is a biopharmaceutical company focused on the discovery, development and commercialization of molecular therapies for the treatment of cancer and other serious diseases.Introgen uses non-integrating gene agents. These agents are designed to increase production of normal cancer-fighting proteins that act to overpower cancerous cells.

The Company has treated hundreds of patients with thousands of doses of its tumor suppressor lead product candidate --ADVEXIN®--.

Introgen's second tumor suppressor product candidate, INGN 241, is in Phase 1-2 clinical development and its third product candidate, INGN 225, a tumor vaccine, is also in Phase 1-2 clinical development. Introgen's clinical trials evaluate its products both alone and in combination with conventional treatments such as chemotherapy, radiation, and surgery.

With the limited efficacy and debilitating toxic effects of conventional cancer treatments, Introgen's low-toxicity approach to cancer treatment has drawn global interest from oncologists.



Pieline for Introgen



ADVEXIN -- Cancer

INGN 241--tumor suppressor product candidate,

INGN 225 -- tumor vaccine




More on Introgen

Home Page

Key Statistics for Introgen

Basic Chart for Introgen

Analyst Opinion

Analysts Estimates


Biotech100 Index
· What are the Requirements to be listed in the Biotech100 Index?
· See the Biotech100 List

Sponsored Links

Clinical Trials
· What is a Clinical Trial?
·Phase I ,-- Phase II, -- PhaseIII
·What is Randomized Control?
 What is a Double Blind Experiment?
·What is the role of the FDA?


Key Biotech Terms


Biotech Resources


Investing in Stocks
· Small Cap Stocks
· Stocks and Bonds
· Biotech100 Index

Careers and Employment
· Biotechnology and Pharmaceutical
· What are the Fastest Growing Careers?




Copyright © 2005 BIOTECH100.COM. All rights reserved.